Preprints.org

Article

Characterization of a C57BL/6J Fancg-KO Mouse Model Generated by CRISPR/Cas9

Ronak Shah , Paul C.M. Van den Berk , Colin E.J. Pritchard , Ji-Ying Song , Maaike Kreft , Bas Pilzecker ,
Heinz Jacobs *

Article

Characterization of a C57BL/6J *Fancg*-KO Mouse Model Generated by CRISPR/Cas9

Ronak Shah [1], Paul C. M. van den Berk [1], Colin E. J. Pritchard [2], Ji-Ying Song [3], Maaike Kreft [1], Bas Pilzecker [1] and Heinz Jacobs [1,*]

[1] Department of Tumor Biology and Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands; r.shah@nki.nl (R.S.); paulvdberk66@gmail.com (P.C.M.v.d.B.); m.kreft@nki.nl (M.K.); baspilzecker@gmail.com (B.P.)

[2] Mouse Clinic for Cancer and Aging Transgenic Facility, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands; c.pritchard@nki.nl

[3] Department of Experimental Animal Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands; j.song@nki.nl

* Correspondence: h.jacobs@nki.nl, Tel.: +31-20-512-2065

Abstract: Fanconi anemia (FA) develops due to a mutation in one of the FANC genes that are involved in repair of interstrand crosslinks (ICLs). FANCG, a member of the FA core complex, is essential for ICL repair. Previous FANCG-deficient mouse models were generated with drug-based selection cassettes in mixed mice backgrounds, leading to a disparity in interpretation of genotype-related phenotype. To exclude these confounders, we created a *Fancg*-KO (KO) mouse model using CRISPR/Cas9. The entire *Fancg* locus was targeted and maintained on the immunological well-characterized C57BL/6J background. Intercrossing of heterozygous mice resulted in sub-Mendelian numbers of homozygous mice, suggesting loss of FANCG can be embryonic lethal. KO mice displayed infertility, hypogonadism but no other developmental problems. Bone marrow analysis revealed a defect in various hematopoietic stem and progenitor subsets with a bias towards myelopoiesis. Cell lines derived from *Fancg*-KO mice were hypersensitive to crosslinking agents-cisplatin and Mitomycin C, and *Fancg*-KO mouse embryonic fibroblasts (MEFs) displayed increased γ-H2AX upon cisplatin treatment. Reconstitution of these MEFs with *Fancg* cDNA corrected for the ICL hypersensitivity. Collectively, this project provides a new, genetically and immunologically well-defined *Fancg*-KO mouse model for further *in vivo* and *in vitro* studies on FANCG and ICL repair.

Keywords: Fanconi anemia (FA); FANCG; interstrand crosslink (ICL); DNA damage response; genetically engineered mouse model (GEMM); CRISPR/Cas9; cisplatin; Mitomycin C (MMC); hematopoiesis

Introduction

Fanconi anemia (FA) is an autosomal recessive human disorder that was first described by Guido Fanconi and is characterized by aplastic anemia, skeletal defects, growth retardation and a predisposition to cancer [1]. FA arises due to a mutation in genes involved in FA repair [2]. The pathway resolves interstrand crosslinks (ICLs), and is regulated by 23 complementation groups of which eight proteins (FANC-A, B, C, E, F, G, L, M) in association with other FA-associated proteins (FAAPs), forms a ubiquitin E3 ligase complex called the FA core complex [3–5]. This complex assembles at the site of the ICL and monoubiquitinates the FANCI-D2 complex [4,6]. Thereafter, a cascade of proteins is recruited to resolve the ICL in an error-free manner [7].

Human *FANCG* is localized to chromosome 9 and was identified to be identical to *XRCC9*, which complemented the MMC-sensitive Chinese hamster mutant UV40 [8–10]. Murine FANCG protein is 83% similar to its human counterpart and its expression in human *Fancg*-deficient lymphoblasts corrects their sensitivity to crosslinks [11]. The protein predominantly localizes to the nucleus and

has two leucine zipper motifs [12]. The protein is most expressed in the testis, spleen and thymus [11]. FANCG interacts with FANCA, FANCC [13,14], is required for the assembly of the FA core complex [15,16] and HR-mediated repair of specific double strand breaks (DSBs) [17].

Genetically engineered mouse models (GEMMs) are an invaluable source to study human diseases as well as uncover the physiological relevance of genes and their regulatory regions in a systemic setting [18,19]. FA is phenotypically heterogenous and mouse models have since been created to recapitulate the FA patient phenotype and understand the relevance of each FA gene in maintaining tissue homeostasis [3,20–22]. These GEMMs also provide a rich source to establish primary as well as transformed cell lines enabling an in-depth *in vitro* characterization of FA proteins and their interactome as part of the DNA damage response (DDR) network. To date, all FA mouse models display reduced fertility and cell line-based hypersensitivity to ICLs [3,20]. Additionally, most models also demonstrate a partial embryonic lethal phenotype, but severe anemia, bone marrow failure and risk of cancer, as observed in FA patients, is not recapitulated in mice, which likely relates to differences in metabolism, life expectancy, and use of alternative ICL repair pathways [20]. Nevertheless, these GEMMs provide a solid platform to screen and test for new therapies, including immunotherapy, that have the potential to improve current standard treatments.

The improvements in genome editing via the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) protein 9 system over the past decade have been phenomenal [23,24]. Borrowed from the prokaryotic cells, the system consists of one or more sequence-specific guide RNAs (gRNA) that identify the target DNA sequence using protospacers adjacent motifs (PAMs) and guide the Cas9 nuclease to cleave this target sequence [25–27]. This results in DSBs that are subsequently repaired, introducing the required genetic modification. CRISPR-Cas9 is highly specific, easy to engineer and a multiplexable tool thereby reducing the time and cost of making models, especially animal models [28,29].

Former *Fancg*-deficient mouse models have been generated on mixed backgrounds, using selection cassettes and partial disruption of the *Fancg* locus [30,31], presenting genotype-phenotype disparities up for discussion. Furthermore, given that immunotherapy is on the forefront of new treatment modalities in genetically instable cancers, the genetic background of these GEMMs becomes relevant in excluding genetic confounders. To accomplish this goal, we generated a C57BL/6J *Fancg*-KO (KO) mouse model using CRISPR/Cas9 technology that employed two RNA guides that induced targeted double strand breaks (DSBs) at each end of the *Fancg* locus. The GEMM was generated and maintained on an immunologically well-defined C57BL/6J background to exclude any confounding phenotypes related to mixed genetic backgrounds. Successful CRISPR/Cas9 mediated ablation of the *Fancg* locus was confirmed by DNA genotyping and cDNA expression. Homozygous mutants were born sub-Mendelian, indicative of embryonic lethality and demonstrated infertility, hematopoietic defects and skewing of hematopoiesis towards the myelopoietic compartment. *Fancg*-KO PreB cells and mouse embryonic fibroblasts (MEFs) displayed hypersensitivity to crosslinking agents-cisplatin and mitomycin C. KO MEFs also displayed levels of γ-H2AX upon cisplatin exposure. Finally, reconstitution with a flagged *Fancg* cDNA- construct fully rescued sensitivity of KO cells to cisplatin, further validating the C57BL/6J *Fancg*-KO mouse model for further fundamental and applied studies in FA research.

Results

Establishing a Genetically and Immunologically Defined C57BL/6J Fancg-KO Mouse Model

Fanconi anemia (FA) complementation group G (*Fancg),* is one of the members of the FA core complex responsible for the ubiquitination of the FANCI-D2 complex. It acts as a scaffold in the formation of the FA core complex [13,15] and is the 3rd most mutated gene in FA patients [32,33]. Murine *Fancg* is located on the chromosome 4, is encoded on the reverse strand and consists of 14 exons (GeneID: 60534) [34]. The *Fancg*-KO (KO) mouse model was generated using C57BL/6J zygotes that were injected with *in vitro* transcribed Cas9 mRNA and two guide RNAs (gRNAs) targeting exon 1 (gRNA1; at chromosomal position -43010202 to 43010221) and 14 of *Fancg* (gRNA2; at chromosomal

position 43002804 to 43002823) (Figure 1A), resulting in a complete deletion of the *Fancg* locus. This gene targeting strategy ensures a pure C57BL/6J genetic background and excludes any potential linkage related mutations associated with long-term embryonic stem cell (ES) culturing. Following the CRISPR/Cas9 procedure, pups were genotyped by PCR using the set of three primers P1, P2 and P3 (Figure 1B), which allowed direct distinction between wild type (WT) and knockout (KO) alleles (Figure 1C), and maintained on a pure C57BL6/J background. Further, deletion of the entire gene was confirmed by genomic PCR and the lack of expression by qRT-PCR (Figure 1D) on cDNA isolated from mouse embryonic fibroblasts (MEFs) (Supplementary Figure S1A). Intercrossing heterozygous *Fancg* mice resulted in expected numbers of WT and heterozygous mice. On the other hand, KO mice were born at a sub-Mendelian frequency, almost 50% less than expected (Figure 1E). Interestingly, we have observed normal KO frequency at E14.5 (Shah et al, unpublished) indicating the homozygous embryos are lost between E14.5 and E21. Nevertheless, homozygous mice that survived this yet-to-be-defined crises developed normally and did not show any growth retardation.

Figure 1. Establishing a genetically and immunologically defined C57BL/6J *Fancg*-KO mouse model. (A) Schematic representation of the *Fancg* locus in the mouse and its CRISPR/Cas9 based inactivation. Cas9 activity targeted by the two gRNAs at *Fancg* locus in exon 1 and 14 is indicated (blue flashes). The product after the 7.5kb DNA fragment deletion is also displayed, and can be detected and distinguished from wild type using the three primers P1, P2 and P3 (black arrows). **(B)** Table lists the sequence of primers used to screen for the knockout of *Fancg* allele and the primer combinations used to detect WT and *Fancg*-KO band simultaneously in one PCR reaction. **(C)**

Genotype PCR distinguishing WT (P1+P2) from KO(P1+P3) allele. (**D**) Using qRT-PCR the lack of exons 2,3, and 4 in the mutant cDNA of *Fancg* was confirmed using the primer pair id 253735709c1 from PrimerBank database. GAPDH was used as internal control and expression was plotted upon normalizing to expression of GAPDH and WT allele. P value was calculated using Welch's t test, ****p<0.0001. (**E**) Observed and expected numbers of offsprings obtained from *Fancg^+/-^* intercrosses. *Fancg*-KO mice were born at sub-Mendelian frequencies. P values were calculated using Pearson's Chi square test, **p<0.01.

C57BL/6J Fancg-KO Mice Display Stem Cell Defects

In mouse tissues, FANCG expression is highest in testes and defects have a profound impact on the reproductive and hematological systems. To assess the impact of a *Fancg* ablation in C57BL/6J mice, we analyzed the bone marrow by multiparametric flowcytometry for hematopoietic progenitors; small intestine, thymus, reproductive organs and sternum by hematoxylin and eosin (H&E) staining; and performed blood smears on 15 WT and 11 KO mice (Figure 2A). Giemsa-Wright-stained blood smears did not reveal any differences between WT and KO conditions, and displayed no signs of anemia (Figure 2B). Histopathological characterization revealed that KO mice were infertile and displayed hypogonadism, characteristic for FA mouse models [1]. For instance, KO male mice had a smaller testis as compared to WT mice (**Figure** 2C, left panel). Further magnification of the H&E sections revealed a complete absence of germ cells, i.e., spermatogonia and spermatocytes; only Sertoli cells could be detected in the lumen (**Figure** 2C, right panel). However, no major pathological alterations were observed in the sternum, thymus and spleen of knockout mice as compared to WT mice.

In FA patients, the failure to repair ICLs impairs hematopoiesis but this has not been consistently observed in FA mouse models. Reasons for these interspecies phenotypic differences relate to differences in metabolism, life-expectancy and differential activation of alternative, though less effective backup pathways of ICL repair [20]. To determine the impact of *Fancg* ablation on murine hematopoiesis, we applied multiparametric flow cytometry. To identify the different hematopoietic progenitors and subset populations, we adopted the gating strategy adapted from Wilson *et al.* [35] (Figure 2D, Supplementary Figure S1B). In normal adult mice, functional HSCs are a part of Lineage (Lin)-negative cells expressing high levels of the c-Kit receptor and stem-cell antigen-1 (Sca-1) (LSK cells) [35,36]. In comparison to the WT mice, the LSK population was significantly reduced in the KO mice (1.4-fold) mice but the HSC population itself was not significantly reduced although a trend could be observed (Figure 2E). The common myeloid progenitors (CMP) and common lymphoid progenitors (CLP) also displayed a drastic reduction. Though the CMP subsets, GMP and MEP, and the MPP subsets, MPP1, Myeloid-primed MPP2-3 did not show any significant differences between WT and KO mice, the lymphoid-primed MPP4s [37] were significantly reduced in KO mice (Figure 2E). Thus, lack of FANCG affects the fitness of the hematopoietic progenitors. The observed reduction of LSK cells and the shifting in the progenitor compartments from lymphoid towards myeloid lineages are indicators of stressed hematopoiesis, consistent with previous studies in other systems [22,36,38]. In summary, while histopathological analysis failed to reveal any signs of anemia, a detailed multiparametric analysis of our KO mouse model clearly identified a bone marrow phenotype. These insights further highlight the critical relevance of FA repair in maintaining tissue homeostasis within the hematopoietic precursor compartment, known to be highly sensitive to endogenous, DNA crosslinking metabolites [39,40].

Figure 2. C57BL/6J *Fancg*-KO mice display stem cell defects. (**A**) WT and KO mice were sacrificed, and various tissues were harvested. Femur and tibia were flushed and used to isolate hematopoietic progenitors that were characterized using a special cocktail described in D using flowcytometry. Other tissues such as the reproductive organs, sternum, spleen were fixed in EAF, processed and stained for H&E. Blood smears were performed by puncturing the heart and stained with the Wright-Giemsa protocol. (**B**) Representative Wright-Giemsa-stained blood smears from WT and KO adult mice. Scale bar: 20 um. (**C**) Sections of testis from WT and KO mice. Wildtype testis are much larger in size than knockout mice (left panel). On zooming in, black arrows indicate normal spermatogenesis (black arrow) in wildtype mice, while knockout mice, filled only by vacuoles (black arrow) and sertoli

cells, indicate severe testicular degeneration and impaired spermatogenesis. Scale bar: 100um. (**D**) Schematic representation of the different hematopoietic subsets identified using defined cell surface markers. (**E**) Numbers of different hematopoietic subsets as defined in Figure 2A. The graphs indicate specific cell counts per $1*10^6$ live cells. In each graph the bar represents the mean ± sd. WT (n=15) and KO (n=11). P values were calculated using one-way ANOVA. *p,0.05, **p<0.01, ***p<0.001, ****p<0.0001.

Fancg-KO Cells Are Hypersensitive to Crosslinking Agents

Cells with inactivating mutations in FA proteins are characterized by their hypersensitivity to DNA crosslinking agents [5,41]. PreB cells established from independent WT and KO fetal livers were either mock-treated or treated with increasing doses of MMC or cisplatin and measured using flowcytometry (Figure 3A,B). Survival analysis revealed that *Fancg*-KO PreB cells were hypersensitive to both crosslinking agents. Similarly, upon measuring proliferation dynamics using the IncuCyte system, Trp53kd *Fancg*-KO MEFs also displayed a hypersensitivity to both crosslinking agents in a dose-dependent manner (Figure 3C,D).

DNA damage, including ICLs, causes replication stress that is accompanied by the phosphorylation of the histone variant H2AX at Ser 139 (γ-H2AX) [42]. Because the formation of γ-H2AX is abundant and fast, it is widely applied as a marker for replication stress and the activation of a DNA damage response (DDR) in general. To identify if absence of FANCG and the concomitant failure to restore ICLs leads to an increased DDR, we exposed WT and KO MEFs with 20 µM cisplatin for an hour and either fixed cells immediately after or after release into normal medium for 4 hours and measured γ-H2AX intensity. Already 1 hour after cisplatin treatment, KO MEFs displayed a significantly increase in the formation of nuclear γH2AX as compared to WT cells. The formation of γ-H2AX further increased after 4 hours indicating that defective ICL repair in KO cells resulted in continued presence of the lesions and thereby, accumulation of γ-H2AX foci.

To validate this model further and provide final proof of the successful inactivation of FANCG in the mouse germline, a functional Flag-tagged *Fancg* cDNA was constructed. The cDNA construct was inserted into a pmx-ires-gfp retroviral vector (Supplementary Figure S1C) allowing the co-expression of GFP and FANCG under the same promoter. Next, the vector was introduced into the WT and KO cells and GFP was used to sort FANCG-FLAG-GFP (FG-gfp) positive cells which were expanded in culture (Figure 3F, Supplementary Figure S1D). IncuCyte experiments were repeated with the newly reconstituted cell lines (WT+FG-gfp and KO+FG-gfp) as well as the WT and KO cells. All four cell lines proliferated at the same rate indicating that the FANCG overexpression did not hamper cellular growth. Upon increasing doses of cisplatin, KO cells, as expected, displayed sensitivity and struggled to proliferate (Figure 3G). On the other hand, the reconstituted KO cells (KO+FG-gfp) displayed normal i.e., wild type sensitivity to this replication stressor. These data demonstrated that the hypersensitivity of the KO to ICLs could be rescued by reintroducing FANCG back into the cells. Taken together, the sensitivity to ICLs, increased DNA damage response and rescue experiments validate our C57BL/6J *Fancg*-KO model which displays all tested characteristics of a FA defect.

Figure 3. *Fancg*-**KO cells are hypersensitive to crosslinking agents.** (**A**,**B**) PreB cells cultured from independent WT or KO fetal livers were exposed to increasing concentrations of (**A**) Mitomycin-C or (**B**) Cisplatin and measured after three days by flowcytometry. Graph displays survival for two independent clones for each genotype, normalized to its untreated condition. Experiment was performed twice. Bar represents mean ± sd. (**C**) *Trp53*kd WT and KO MEFs were seeded at 250 cells/well in a 96-well plate and treated with two different doses of cisplatin (80 and 160 nM) a day later. Cell confluency was measured every 4 hours using IncuCyte live cell imaging system from two independent experiments. Analysis was performed for timepoint when WT samples reached 50% confluency. Dots at each timepoint indicate mean and bars represent sd. (**D**) *Trp53*kd WT and KO MEFs were seeded at 250 cells/well in a 96-well plate and treated with two different doses of MMC (15 and 30 nM) a day later. Cell confluency was measured every 4 hours using IncuCyte live cell imaging system from two independent experiments. Analysis was performed for timepoint when WT samples reached 50% confluency. Dots at each timepoint indicate mean and bars represent sd. (**E**) *Trp53*kd WT and KO MEFs were seeded on coverslips and treated with 20 μM cisplatin. After 1 hr, one batch of cells was fixed while other batch was refreshed with medium and fixed 4 hrs later. Cells were stained for γ-H2aX and nuclear intensity was measured using a microscope. Graphs display intensity as fold change relative to WT. (**F**) Schematic displaying the protocol utilized to obtain stable WT/KO MEFs expressing the Fancg-flag-gfp overexpression construct. *Trp53*kd MEFs were retrovirally transfected with the pmx vector, sorted for GFP expression and expanded for further use. (**G**) TP53kd WT, KO, WT+FG-gfp and KO+FG-gfp MEFs were seeded at 250 cells/well in a 96-well

plate. Cell confluency was measured with/without Cisplatin every 4 hours using IncuCyte live cell imaging system from two independent experiments. Dots at each timepoint indicate mean and bars represent sd.

Discussion

Crosslinking agents are widely applied in cancer therapy as they introduce one of the most toxic DNA lesions i.e., interstrand crosslinks (ICLs). These lesions are effectively repaired by the Fanconi anemia (FA) repair pathway. Inactivation of one of the FA repair components can lead to pleiotropic defects such as aplastic anemia, congenital abnormalities and skeletal retardation in FA patients. While genetically engineered mouse models (GEMMs) fail to recap all of the phenotypes seen in FA patients, the common hypersensitivity to ICLs studies closely recapitulate those of FA patients and cells. In this regard, FA GEMMs and cell lines thereof provide ideal model systems to study the relevance of FA-ICL repair in stem cell maintenance and hematopoiesis. Applying the CRISPR/Cas9 technology in C57BL/6J zygotes we generated and characterized a novel, genetically and immunologically well-defined C57BL/6J *Fancg*-KO mouse model. To exclude the possibility of generating hypomorphic gene products, the entire *Fancg* locus was deleted. Ablation of the *Fancg* locus was verified by genotyping and RNA expression. In contrast to conventional KO approaches, this gene targeting strategy excludes experimental confounders related to mixed backgrounds and the co-segregating of modulators and other unrelated genetically linked phenotypesx [30,31]. The exclusion of such confounder warrants conclusive genotype-phenotype interactions.

To minimize genetic drifting, *Fancg* mutant mice were maintained on a C57BL/6J background. To derive homozygous mutants, heterozygous *Fancg* mice were intercrossed. KO mice were obtained at a sub-Mendelian frequency, suggesting that homozygous condition causes embryonic lethality, similar to recent observations made for a *Fanci*[-/-] model [21] (Figure 1E), but contrasting previous observations made in independent *Fancg* mouse models [30,31]. In these reports, *Fancg*[-/-] mice were born at a normal Mendelian frequency. However, these studies used mice with mixed backgrounds [30,31], a potential confounder that could mask specific genotype-phenotype interactions. As we observe expected *Fancg*-KO numbers at E14.5 but not at weaning (E21), the FANCG-deficient embryos apparently experience a specific stress condition prior to weaning, a phenotype that necessitates future in depth studies. Nevertheless, consistent with other FA mouse models in previous studies, our KO mice were also infertile with gross germ cell defects and reduced size of testes/ovaries which might be due to the RAC1-based exhaustion of primordial germ cells in the absence of FANCG [43]. Otherwise *Fancg*-KO developed normally without any overt macroscopic abnormalities. Consistently, none of the tissues examined microscopically displayed any obvious pathological features.

Regarding the involvement of FA pathway in hematopoiesis, the *Fancg*[-/-] mouse models studied thus far did not reveal hematological defects based on blood cell counts, hemoglobin analysis and blood smears [30,31,36,44,45]. Similar to other FA mice [22,38,46,47], the blood smears of our KO mice showed no signs of anemia indicating that unlike FA patients spontaneous anemia inflicted by reactive crosslinking metabolites does not occur in mice [40]. Therefore, the anemic phenotype in humans might be visualized better by the disruption of more than one gene in the FA pathway in mice [36,48], as shown previously in compound GEMMs lacking *Fancc* and *Fancg* [36].

Regarding hematopoietic subsets, the bone marrow of our KO mice shows a significant reduction in early progenitors i.e., LSK subset which is in line with observations made by Barroca *et al.* in their *Fancg*[-/-] mice [44] and other FA mouse models [48–50]. We also noted similarities regarding the common lymphoid and myeloid progenitors (CLP & CMP), although we did not observe a significant reduction in the GMP and MEP subsets. While Barroca *et al.* use CD34 and CD135 (*Flk2*) to define their short term and long-term HSCs [44], we utilized a more comprehensive panel including SLAM receptors [51] CD150 and CD48 to define our HSC and MPP populations as described by Wilson *et al.* [35]. Interestingly, their short-term HSCs (LSKCD34[+]Flk2[-]) are equivalent to our MPP1-3 and their MPPs (LSKCD34[+]FLk2[+]) equivalent to our MPP4 populations, and display similar behaviour. However, unlike their long-term HSCs (LSKCD34[-]Flk2[-]), we do not see a

significant drop in our HSCs (LSKCD34⁻CD48⁻CD150⁺CD135⁻). In summary, both models revealed an important role of FANCG in myelopoiesis and lymphopoiesis. Additionally, our data demonstrates that lymphoid progenitors (CLPs and MPP4s) are compromised, likely to sustain the differentiation of myeloid progenitors GMP and MEPs, a hallmark of stressed hematopoiesis.

The most stable FA phenotype relates to the hypersensitivity to crosslinking agents [21]. PreBs and MEFs derived from our KO mice were, as expected, hypersensitive to both cisplatin and MMC. We were able to rescue this sensitivity by retroviral transduction of a wild type murine *Fancg* cDNA. In addition, this construct possesses Flag tags flanking FANCG which can be utilized to perform immunoprecipitation-based studies and provides a solution for the lack of efficient anti-mFANCG antibodies in the market for biochemistry and molecular biology-based experiments.

In summary, we present here a new, genetically and immunologically well-defined C57Bl/6J *Fancg*-KO mouse model carrying a complete ablation of the *Fancg* locus that presents key characteristics of FA phenotypes. In addition to the mouse model, cells derived thereof as well as their reconstituted counterparts provide an opportunity to study FA repair, particularly the role of FANCG under specific ICL stress conditions caused by metabolites as well as chemotherapeutics.

Materials and Methods

Generation of Fancg⁻/⁻ Mouse

A *Fancg*-KO mouse model was generated wherein C57BL/6J zygotes were injected with *in vitro* transcribed Cas9 mRNA and two guide RNAs (gRNAs) targeting *Fancg* [29,52]. The 2 gRNAs targeting exon 1 and 14 were designed using the crispr.mit.edu tool and transcribed *in vitro* from PCR templates that had a T7 promoter. To distinguish wildtype and homozygous mutants, we established a three primer PCR strategy. Pups born were selected for the knock out allele, backcrossed once onto C57BL6/J and maintained for the desired experimental genotype.

Generation of Primary Cell-Lines and Cell Culture

Timed-matings of *Fancg⁺/⁻* females were set up with corresponding males to obtain embryos. On day 14.5 of gestation, embryos were isolated to prepare primary mouse embryonic fibroblasts (pMEFs). From Fetal liver, Pre-B cell cultures were established by culturing on irradiated ST2 feeder cells in complete IMDM medium (Iscoves, supplemented with 8% fetal calf serum (FCS), 50 μM 2-mercapthoethanol, penicillin/streptomycin) supplemented with IL-7 containing supernatant [53]. Primary MEFs (2, from independent embryos per genotype) were isolated using Trypsin and cell strainers and cultured under low (3%) oxygen condition, with 5% CO_2 at 37°C. To immortalize MEFs, pMEFs were transduced with a lentivirus encoding a p53-specific shRNA [54]. The immortalized *Trp53*kd MEFs were grown in complete IMDM medium under normal oxygen levels with 5% CO_2 at 37°C.

PCR Genotyping

Genomic DNA was extracted from mouse toe tips and used as template for polymerase chain reaction (PCR) genotyping. The PCR protocol was: 95°C for 2 min and then 40 cycles of 95°C for 30 s, 58°C for 40 s and 72°C for 1 min; last 5 min at 72°C.

qRT-PCR

RNeasy mini (Qiagen) was used to isolate total RNA from wild type and *Fancg*-KO MEFs for qRT-PCR. The cDNA libraries were synthesized using Invitrogen Superscript III kit and random hexamer primers. *Fancg* was amplified with high fidelity PfuUltra Hotstart DNA polymerase (Stratagene) using gene specific primers (id: 253735709c1) from PrimerBank database [55].

Immunofluorescence of Bone Marrow (BM) Cells

Mice were euthanized at indicated age (8-16 weeks), and BM cells from femur and tibia were flushed out using 21 Gauge syringes in cold PBEA buffer (1x PBS, 0.5% BSA, 2mM EDTA, 0.02% Sodium Azide). Eythrocytes were eliminated from the BM cells using an erylysis buffer (NH_4Cl, $KHCO_3$, 0.5M EDTA) and passed through a 70 μm filter. 10 million cells were used for staining. The following antibodies were used: Mouse Lineage Cell Detection Cocktail biotin antibody (1:40) followed by c-kit-APC (Clone 2B8, eBioscience), Streptavidin-APC-Cy7 (Southern Biotech), CD135-PE (Clone A2F10), CD48-PE-Dazzle (Clone HM48-1), Sca1-PE-Cy7 (Clone D7), CD34-FITC (Clone RAM34, Invitrogen, 1:100), CD127-BV421 (Clone A7R34), CD150-BV650 (Clone TC15-12F12.2), CD16/32-BV786 (clone 2.4G2, BD Bioscience). Dead cells were excluded by 7AAD staining. All the antibodies for FACS analysis were from Biolegend and used 1:200, unless otherwise specified.

Histopathology

Spleen, thymus, sternum and testis/ovary were collected and fixed in ethanol-(not glacial) acetic acid-formalin (EAF). Samples were embedded in paraffin, sections of 4 μm thickness were made and stained for Hematoxylin and eosin (H&E). The sections were reviewed with a Zeiss AxiosKOp2 Plus microscope (Carl Zeiss Microscopy, Jena, Germany), and images were captured with a Zeiss AxioCam HRc digital camera and processed with AxioVision 4 software (both from Carl Zeiss Vision, München, Germany). The scale bars were set at 50 μm. Blood smears were stained with Wright-Giemsa stain.

PreB Survival Assay

Survival assay was performed as described previously [53]. Briefly, 10^5 pre-B cells were seeded in 12-wells plates containing an ST2 feeder layer and 1 ml complete medium and IL-7 in the continuous presence of different doses of the cisplatin or MMC. To determine cell survival, cells were harvested after 3 days of culture and stained with DAPI. The number of DAPI-negative cells was measured on a Fortessa (Becton Dickinson). Data analysis was performed with FlowJo software.

IncuCyte Proliferation Assay

The IncuCyte ZOOM instrument (Essen Bioscience) live cell imaging system was used to monitor cell growth of MEFs. 250 cells were plated in a 96 Greiner micro clear black well plate and imaged every 4 hours (hrs) in the presence or absence of cisplatin or MMC. The default software parameters for a 96 well plate with a 10x objective were used for imaging. The IncuCyte software was used to calculate mean confluence from four non-overlapping bright phase images of each well.

γ-H2AX Immunofluorescence

Immunofluorescence was performed as described previously. Cells were grown on coverslips for a day before the treatment with 20 μM CsPt for 1 hr. After treatment, one batch was placed on ice and the second batch was refreshed with medium. After 4 hrs, both batches of cells were washed with PBS and pre-extracted with PBS/0.5%TritonX-100) on ice for 1 minute. Cells were then fixed using 4% Formaldehyde for 15 mins at room temperature (RT). Fixed cells were then incubated with primary Abs against γ-H2AX at RT for 90 mins. Cells were washed and incubated with secondary Abs alongside DAPI for 1 hr at RT. After washing, coverslips were mounted onto glass slides using Aqua Poly/Mount. Pictures were taken with a Zeiss AxioObserver Z1 inverted microscope using a 63x lens equipped with a cooled Hamamatsu ORCA AG Black and White CCD camera. Nuclear intensities were measured using a macro designed with ImageJ software.

Fancg-Flag Reconstitution

Mouse *Fancg* cDNA sequence was obtained from Ensembl. The cDNA sequence was flanked on both ends by 2 glycine residues and a Flag tag. *Fancg*-Flag sequence was ordered as a geneblock from

Integrated DNA Technologies (IDT). The sequence was cloned into pMX-IRES-GFP plasmid (Supplementary Figure S1). The orientation and insertion of the geneblock was confirmed using three primer sets (Table 1). To transduce the *Trp53*kd MEFs with *Fancg*-Flag cDNA, HEK293T cells were seeded in a 10 cm dish. The following day, HEK293T cells were transfected with 6 μl X-tremeGENE (Roche), 194 μl of serum free medium (SFM) and incubated for 5 mins at RT. 2 μg of pMX-*Fancg*-Flag-IRES-GFP and packaging vector (pCL-Eco) were added in a total of 200 μl Serum Free Medium. The ratio of X-tremeGENE to total DNA was 3:1 while that for the plasmid to pCL-Eco was 3:2. Both X-tremeGENE and plasmid mix were put together and incubated for 30 mins at RT. Following incubation, 400 μl of the final mixture was added dropwise to each well already containing 1.6 ml of complete IMDM medium. These cells were cultured under standard conditions for 48 hrs after which the supernatant containing retroviral particles was collected. Polybrene® (10 mg/ml) was added to the supernatant at a final concentration of 1 mg/ml. 2 ml of virus supernatant was added to 500,000 MEFs. After 5 days, cells were harvested and sorted for positive GFP expression to be further used for culture.

Table 1. Sequence of primers used to screen for the insertion of the customized *Fancg* geneblock in the pMX-IRES-GFP plasmid.

Name	Sequence (5'-3')
pmxFG_Internal primer A fwd	GAGGGATGTCCTTCTGACTGC
pmxFG_Internal primer A rev	GAGAACCTTGTCTCTGAGCCACCC
pmxFG_Internal primer B fwd	CTGCCGTGTTGCCCAGTCTGGGTC
pmxFG_Internal primer B rev	GGCTTCGCGGTTAGGGGGATGGAT
pmxFG_Internal primer C fwd	TCTTCCACTGTATTTAGAAACCTG
pmxFG_Internal primer C rev	TTATACACGTGGCTTTTGGCCGCA

Statistical Analysis

To assess the statistical significance of our data appropriate tests were performed using GraphPad Prism

Author Contributions: R.S. and H.J. designed the study. B.P. and C.P. designed the guides and strategy for the mouse model. C.P. made the mouse model. P.vdB. maintained the mouse line. R.S., M.K. and P.vdB. performed the *ex vivo* experiments. R.S. made the cell lines and performed the *in vitro* experiments. J.S. analyzed all the pathology slides. R.S. and H.J. wrote the manuscript.

Institutional Board Review Statement: Experiments were approved by an independent animal ethics committee of the Netherlands Cancer Institute (Amsterdam, Netherlands) (DEC number 14053) and executed according to Dutch and European guidelines.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. T. Yamashita and T. Nakahata, "Current Knowledge on the Pathophysiology of Fanconi Anemia: From Genes to Phenotypes," *Int. J. Hematol.*, vol. 74, no. 1, pp. 33–41, Jul. 2001, doi: 10.1007/BF02982547.

2. R. Ceccaldi, P. Sarangi, and A. D. D'Andrea, "The Fanconi anaemia pathway: new players and new functions," *Nat. Rev. Mol. Cell Biol.*, vol. 17, no. 6, pp. 337–349, Jun. 2016, doi: 10.1038/nrm.2016.48.

3. R. Errazquin *et al.*, "Development of a mouse model for spontaneous oral squamous cell carcinoma in Fanconi anemia," *Oral Oncol.*, vol. 134, p. 106184, Nov. 2022, doi: 10.1016/j.oraloncology.2022.106184.

4. G. Nalepa and D. W. Clapp, "Fanconi anaemia and cancer: an intricate relationship," *Nat. Rev. Cancer*, vol. 18, no. 3, pp. 168–185, Mar. 2018, doi: 10.1038/nrc.2017.116.

5. R. Che, J. Zhang, M. Nepal, B. Han, and P. Fei, "Multifaceted Fanconi Anemia Signaling," *Trends Genet.*, vol. 34, no. 3, pp. 171–183, Mar. 2018, doi: 10.1016/j.tig.2017.11.006.

6. A. F. Alpi and K. J. Patel, "Monoubiquitylation in the Fanconi anemia DNA damage response pathway," *DNA Repair*, vol. 8, no. 4, pp. 430–435, Apr. 2009, doi: 10.1016/j.dnarep.2009.01.019.

7. M. C. Kottemann and A. Smogorzewska, "Fanconi anaemia and the repair of Watson and Crick DNA crosslinks," *Nature*, vol. 493, no. 7432, Art. no. 7432, Jan. 2013, doi: 10.1038/nature11863.

8. J. P. de Winter *et al.*, "The Fanconi anaemia group G gene FANCG is identical with XRCC9," *Nat. Genet.*, vol. 20, no. 3, pp. 281–283, Nov. 1998, doi: 10.1038/3093.

9. N. Liu *et al.*, "The human XRCC9 gene corrects chromosomal instability and mutagen sensitivities in CHO UV40 cells," *Proc. Natl. Acad. Sci.*, vol. 94, no. 17, pp. 9232–9237, Aug. 1997, doi: 10.1073/pnas.94.17.9232.

10. K. Saar *et al.*, "Localisation of a Fanconi anaemia gene to chromosome 9p," *Eur. J. Hum. Genet.*, vol. 6, no. 5, Art. no. 5, Sep. 1998, doi: 10.1038/sj.ejhg.5200241.

11. H. J. Van De Vrugt *et al.*, "Characterization, expression and complex formation of the murine Fanconi anaemia gene product Fancg," *Genes Cells*, vol. 7, no. 3, pp. 333–342, 2002, doi: 10.1046/j.1365-2443.2002.00518.x.

12. I. Demuth *et al.*, "Spectrum of mutations in the Fanconi anaemia group G gene, FANCG/XRCC9," *Eur. J. Hum. Genet. EJHG*, vol. 8, no. 11, pp. 861–868, Nov. 2000, doi: 10.1038/sj.ejhg.5200552.

13. I. Garcia-Higuera, Y. Kuang, D. Näf, J. Wasik, and A. D. D'Andrea, "Fanconi anemia proteins FANCA, FANCC, and FANCG/XRCC9 interact in a functional nuclear complex," *Mol. Cell. Biol.*, vol. 19, no. 7, pp. 4866–4873, Jul. 1999, doi: 10.1128/MCB.19.7.4866.

14. Q. Waisfisz *et al.*, "A physical complex of the Fanconi anemia proteins FANCG/XRCC9 and FANCA," *Proc. Natl. Acad. Sci. U. S. A.*, vol. 96, no. 18, pp. 10320–10325, Aug. 1999, doi: 10.1073/pnas.96.18.10320.

15. I. Garcia-Higuera, Y. Kuang, J. Denham, and A. D. D'Andrea, "The fanconi anemia proteins FANCA and FANCG stabilize each other and promote the nuclear accumulation of the Fanconi anemia complex," *Blood*, vol. 96, no. 9, pp. 3224–3230, Nov. 2000.

16. J. P. de Winter *et al.*, "The Fanconi anemia protein FANCF forms a nuclear complex with FANCA, FANCC and FANCG," *Hum. Mol. Genet.*, vol. 9, no. 18, pp. 2665–2674, Nov. 2000, doi: 10.1093/hmg/9.18.2665.

17. K. Yamamoto *et al.*, "Fanconi anemia FANCG protein in mitigating radiation- and enzyme-induced DNA double-strand breaks by homologous recombination in vertebrate cells," *Mol. Cell. Biol.*, vol. 23, no. 15, pp. 5421–5430, Aug. 2003, doi: 10.1128/MCB.23.15.5421-5430.2003.

18. K. Kersten, K. E. de Visser, M. H. van Miltenburg, and J. Jonkers, "Genetically engineered mouse models in oncology research and cancer medicine," *EMBO Mol. Med.*, vol. 9, no. 2, pp. 137–153, Feb. 2017, doi: 10.15252/emmm.201606857.

19. W. Hill, D. R. Caswell, and C. Swanton, "Capturing cancer evolution using genetically engineered mouse models (GEMMs)," *Trends Cell Biol.*, vol. 31, no. 12, pp. 1007–1018, Dec. 2021, doi: 10.1016/j.tcb.2021.07.003.

20. S. T. Bakker, J. P. de Winter, and H. te Riele, "Learning from a paradox: recent insights into Fanconi anaemia through studying mouse models," *Dis. Model. Mech.*, vol. 6, no. 1, pp. 40–47, Jan. 2013, doi: 10.1242/dmm.009795.

21. E. L. Dubois *et al.*, "A Fanci knockout mouse model reveals common and distinct functions for FANCI and FANCD2," *Nucleic Acids Res.*, vol. 47, no. 14, pp. 7532–7547, Aug. 2019, doi: 10.1093/nar/gkz514.

22. N. C. Cheng *et al.*, "Mice with a targeted disruption of the Fanconi anemia homolog Fanca," *Hum. Mol. Genet.*, vol. 9, no. 12, pp. 1805–1811, Jul. 2000, doi: 10.1093/hmg/9.12.1805.

23. J. D. Sander and J. K. Joung, "CRISPR-Cas systems for editing, regulating and targeting genomes," *Nat. Biotechnol.*, vol. 32, no. 4, pp. 347–355, Apr. 2014, doi: 10.1038/nbt.2842.

24. F. Zhang, Y. Wen, and X. Guo, "CRISPR/Cas9 for genome editing: progress, implications and challenges," *Hum. Mol. Genet.*, vol. 23, no. R1, pp. R40–R46, Sep. 2014, doi: 10.1093/hmg/ddu125.

25. M. Jinek, K. Chylinski, I. Fonfara, M. Hauer, J. A. Doudna, and E. Charpentier, "A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity," *Science*, vol. 337, no. 6096, pp. 816–821, Aug. 2012, doi: 10.1126/science.1225829.

26. L. Cong *et al.*, "Multiplex genome engineering using CRISPR/Cas systems," *Science*, vol. 339, no. 6121, pp. 819–823, Feb. 2013, doi: 10.1126/science.1231143.

27. W. Jiang, D. Bikard, D. Cox, F. Zhang, and L. A. Marraffini, "RNA-guided editing of bacterial genomes using CRISPR-Cas systems," *Nat. Biotechnol.*, vol. 31, no. 3, Art. no. 3, Mar. 2013, doi: 10.1038/nbt.2508.

28. B. Shen *et al.*, "Generation of gene-modified mice via Cas9/RNA-mediated gene targeting," *Cell Res.*, vol. 23, no. 5, pp. 720–723, May 2013, doi: 10.1038/cr.2013.46.

29. H. Wang *et al.*, "One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering," *Cell*, vol. 153, no. 4, pp. 910–918, May 2013, doi: 10.1016/j.cell.2013.04.025.

30. M. Koomen *et al.*, "Reduced fertility and hypersensitivity to mitomycin C characterize Fancg/Xrcc9 null mice," *Hum. Mol. Genet.*, vol. 11, no. 3, pp. 273–281, Feb. 2002, doi: 10.1093/hmg/11.3.273.

31. Y. Yang *et al.*, "Targeted disruption of the murine Fanconi anemia gene,Fancg/Xrcc9," *Blood*, vol. 98, no. 12, pp. 3435–3440, Dec. 2001, doi: 10.1182/blood.V98.12.3435.

32. D. I. Kutler *et al.*, "A 20-year perspective on the International Fanconi Anemia Registry (IFAR)," *Blood*, vol. 101, no. 4, pp. 1249–1256, Feb. 2003, doi: 10.1182/blood-2002-07-2170.

33. C. G. Mathew, "Fanconi anaemia genes and susceptibility to cancer," *Oncogene*, vol. 25, no. 43, Art. no. 43, Sep. 2006, doi: 10.1038/sj.onc.1209878.

34. E. W. Sayers *et al.*, "Database resources of the national center for biotechnology information," *Nucleic Acids Res.*, vol. 50, no. D1, pp. D20–D26, Jan. 2022, doi: 10.1093/nar/gkab1112.

35. A. Wilson *et al.*, "Hematopoietic Stem Cells Reversibly Switch from Dormancy to Self-Renewal during Homeostasis and Repair," *Cell*, vol. 135, no. 6, pp. 1118–1129, Dec. 2008, doi: 10.1016/j.cell.2008.10.048.

36. A. C. Pulliam-Leath *et al.*, "Genetic disruption of both Fancc and Fancg in mice recapitulates the hematopoietic manifestations of Fanconi anemia," *Blood*, vol. 116, no. 16, pp. 2915–2920, Oct. 2010, doi: 10.1182/blood-2009-08-240747.

37. E. M. Pietras *et al.*, "Functionally Distinct Subsets of Lineage-Biased Multipotent Progenitors Control Blood Production in Normal and Regenerative Conditions," *Cell Stem Cell*, vol. 17, no. 1, pp. 35–46, Jul. 2015, doi: 10.1016/j.stem.2015.05.003.

38. M. Chen *et al.*, "Inactivation of Fac in mice produces inducible chromosomal instability and reduced fertility reminiscent of Fanconi anaemia," *Nat. Genet.*, vol. 12, no. 4, pp. 448–451, Apr. 1996, doi: 10.1038/ng0496-448.

39. J. I. Garaycoechea *et al.*, "Alcohol and endogenous aldehydes damage chromosomes and mutate stem cells," *Nature*, vol. 553, no. 7687, Art. no. 7687, Jan. 2018, doi: 10.1038/nature25154.

40. M. Wang, F. A. Dingler, and K. J. Patel, "Genotoxic aldehydes in the hematopoietic system," *Blood*, vol. 139, no. 14, pp. 2119–2129, Apr. 2022, doi: 10.1182/blood.2019004316.

41. A. J. Deans and S. C. West, "DNA interstrand crosslink repair and cancer," *Nat. Rev. Cancer*, vol. 11, no. 7, Art. no. 7, Jul. 2011, doi: 10.1038/nrc3088.

42. I. M. Ward and J. Chen, "Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress," *J. Biol. Chem.*, vol. 276, no. 51, pp. 47759–47762, Dec. 2001, doi: 10.1074/jbc.C100569200.

43. A. Jarysta *et al.*, "Abnormal migration behavior linked to Rac1 signaling contributes to primordial germ cell exhaustion in Fanconi anemia pathway-deficient Fancg-/- embryos," *Hum. Mol. Genet.*, vol. 31, no. 1, pp. 97–110, Dec. 2021, doi: 10.1093/hmg/ddab222.

44. V. Barroca *et al.*, "Impaired functionality and homing of Fancg-deficient hematopoietic stem cells," *Hum. Mol. Genet.*, vol. 21, no. 1, pp. 121–135, Jan. 2012, doi: 10.1093/hmg/ddr447.

45. Y. Li *et al.*, "Mesenchymal stem/progenitor cells promote the reconstitution of exogenous hematopoietic stem cells in Fancg−/− mice in vivo," *Blood*, vol. 113, no. 10, pp. 2342–2351, Mar. 2009, doi: 10.1182/blood-2008-07-168138.

46. M. A. Whitney *et al.*, "Germ cell defects and hematopoietic hypersensitivity to gamma-interferon in mice with a targeted disruption of the Fanconi anemia C gene," *Blood*, vol. 88, no. 1, pp. 49–58, Jul. 1996.

47. M. A. Whitney, P. Jakobs, M. Kaback, R. E. Moses, and M. Grompe, "The Ashkenazi Jewish Fanconi anemia mutation: incidence among patients and carrier frequency in the at-risk population," *Hum. Mutat.*, vol. 3, no. 4, pp. 339–341, 1994, doi: 10.1002/humu.1380030402.

48. Y. Zhou *et al.*, "An abnormal bone marrow microenvironment contributes to hematopoietic dysfunction in Fanconi anemia," *Haematologica*, vol. 102, no. 6, pp. 1017–1027, Jun. 2017, doi: 10.3324/haematol.2016.158717.

49. K. Parmar *et al.*, "Hematopoietic stem cell defects in mice with deficiency of Fancd2 or Usp1," *Stem Cells Dayt. Ohio*, vol. 28, no. 7, pp. 1186–1195, Jul. 2010, doi: 10.1002/stem.437.

50. J. M. Kim *et al.*, "Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype," *Dev. Cell*, vol. 16, no. 2, pp. 314–320, Feb. 2009, doi: 10.1016/j.devcel.2009.01.001.

51. A. Veillette, "SLAM-Family Receptors: Immune Regulators with or without SAP-Family Adaptors," *Cold Spring Harb. Perspect. Biol.*, vol. 2, no. 3, p. a002469, Mar. 2010, doi: 10.1101/cshperspect.a002469.

52. C. E. J. Pritchard, L. J. Kroese, and I. J. Huijbers, "Direct Generation of Conditional Alleles Using CRISPR/Cas9 in Mouse Zygotes," in *Site-Specific Recombinases: Methods and Protocols*, N. Eroshenko, Ed., in Methods in Molecular Biology. New York, NY: Springer, 2017, pp. 21–35. doi: 10.1007/978-1-4939-7169-5_2.

53. N. Wit *et al.*, "Roles of PCNA ubiquitination and TLS polymerases κ and η in the bypass of methyl methanesulfonate-induced DNA damage," *Nucleic Acids Res.*, vol. 43, no. 1, pp. 282–294, Jan. 2015, doi: 10.1093/nar/gku1301.

54. A. M. G. Dirac and R. Bernards, "Reversal of Senescence in Mouse Fibroblasts through Lentiviral Suppression of p53*210," *J. Biol. Chem.*, vol. 278, no. 14, pp. 11731–11734, Apr. 2003, doi: 10.1074/jbc.C300023200.

55. X. Wang, A. Spandidos, H. Wang, and B. Seed, "PrimerBank: a PCR primer database for quantitative gene expression analysis, 2012 update," *Nucleic Acids Res.*, vol. 40, no. Database issue, pp. D1144–D1149, Jan. 2012, doi: 10.1093/nar/gkr1013.